Proto Labs (PRLB) Form 144: Proposed Sale of 3,048 Shares

Proto Labs (PRLB) has a Form 144 notice for a proposed sale of 3,048 shares of its common stock.

Rhea-AI Filing Summary

Proto Labs (PRLB) has a Form 144 notice for a proposed sale of 3,048 shares of its common stock. The shares are planned to be sold through Morgan Stanley Smith Barney LLC on the NYSE, with an indicated aggregate market value of $150,144.48. The filing notes that 23,678,745 shares of common stock were outstanding when the notice was prepared.

The seller acquired the 3,048 shares on 11/25/2025 by exercising stock options granted by the issuer and paid the purchase price in cash on the same date. The Form 144 also includes the standard representation that the seller does not know of any undisclosed material adverse information about Proto Labs’ current or prospective operations.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Proto Labs (PRLB) disclose in this Form 144 filing?

The Form 144 reports a planned sale of 3,048 common shares of Proto Labs stock, acquired via stock option exercise and to be sold on the NYSE through a broker.

How many Proto Labs (PRLB) shares are proposed to be sold under this Form 144?

The notice covers a proposed sale of 3,048 shares of Proto Labs common stock.

What is the aggregate market value of the PRLB shares in this Form 144?

The filing reports an aggregate market value of $150,144.48 for the 3,048 Proto Labs shares proposed to be sold.

How were the Proto Labs (PRLB) shares in this Form 144 acquired?

The 3,048 shares were acquired on 11/25/2025 through the exercise of stock options granted by the issuer, with the purchase price paid in cash.

How many Proto Labs (PRLB) shares were outstanding at the time of the notice?

The Form 144 states that 23,678,745 shares of Proto Labs common stock were outstanding when the notice was prepared.

Which broker and exchange are involved in this Proto Labs (PRLB) Form 144 sale?

The filing lists Morgan Stanley Smith Barney LLC as the broker and the NYSE as the securities exchange for the planned sale.

Does the Proto Labs (PRLB) Form 144 mention undisclosed adverse information?

By signing the notice, the seller represents that they do not know of any material adverse information about Proto Labs’ operations that has not been publicly disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/25/2025 - 04:25 PM EST Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001870293
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Proto Labs, Inc.
SEC File Number	001-35435
Address of Issuer	5540 Pioneer Creek Drive Maple Plain MINNESOTA 55359
Phone	7634793680
Name of Person for Whose Account the Securities are To Be Sold	MICHAEL KENISON
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	3048	150144.48	23678745	11/25/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	11/25/2025	Exercise of Stock Options	Issuer			3048	11/25/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	11/25/2025
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	08/15/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Michael Kenison
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)